In the past decade, it has become clear that the immune system can be manipulated to induce cancer regression, durable disease stabilization, and long-term survival in a substantial fraction of cancer patients. Building on this success, members of the Immunology and Cancer (IC) Program aim to better understand the interface between the host immune system and a malignant tumor, and to use this knowledge to develop more effective immunotherapies for the treatment of a broad array of cancer types. The central themes of the Program include: 1) basic immunology relevant to the cancer context (including innate immunity, lymphocyte activation, and peripheral inflammation/tolerance regulation); 2) preclinical mouse models of anti-tumor immunity; and 3) human cancer immunology and immunotherapy. Through the pursuit of these themes, IC members have made fundamental discoveries regarding immune regulation and anti-tumor immunity, and in collaboration with clinical colleagues in the Clinical and Experimental Therapeutics (CET) Program, have leveraged many of these concepts for the development of novel immunotherapies that are now being evaluated in the clinic. The Program is co-led by Thomas Gajewski, MD PhD, Professor of Pathology and Medicine, and Peter Savage, PhD, Associate Professor of Pathology. Dr. Gajewski is a physician-scientist and international leader in the field of tumor immunology and the successful implementation of cancer immunotherapy in human patients. Dr. Savage is a recognized leader in the study of regulatory T cell biology and the role of these cells in the regulation of anti-tumor immunity. There are 18 program members from seven Departments. The IC Program has recruited five new faculty since 2013, including Jason Luke, MD, Melody Swartz, PhD, Jun Huang, PhD, Seungmin Hwang, PhD, and James Labelle, MD, PhD. During the last funding period (2013-2016), program members have published 224 cancer-related articles (with 13% intraprogrammatic and 19% interprogrammatic publications). As of January 2017, Program members hold 36 grants, and are supported by $6.6M (direct costs) in NIH extramural funding, including 6 grants and $1.0M (direct costs) from the NCI. Program members are supported by an additional $2.23 M (direct costs) in non- peer-reviewed support, resulting in total support of $8.9 M (direct costs).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-43
Application #
9489801
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-22
Budget End
2019-03-31
Support Year
43
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 668 publications